XML 77 R59.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Significant Agreements (Details) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 03, 2018 USD ($) shares | Dec. 31, 2021 USD ($) item | Jan. 31, 2016 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) item | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Feb. 26, 2010 USD ($)
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 77,428,000 | $ 23,638,000 | $ 3,154,000 |  |  |
One-time non-refundable development milestone payment | $ 70,000,000 |  |  |  |  |  |  |  |  |  |
RareStone Group Ltd. |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Number of independent sub studies in patients | item |  |  |  |  |  |  |  | 4 |  |  |
Upfront payment |  | $ 7,000,000 |  |  |  |  |  |  |  |  |
Equity issued in conjunction with license agreement |  | 1,077,586 |  |  |  |  |  |  |  |  |
Aggregate payment upon achievement of development and commercial milestones |  | 62,500,000 |  |  |  |  |  | $ 62,500,000 |  |  |
Equity recorded at fair value |  | $ 1,040,000 |  |  | $ 1,040,000 |  |  | 1,040,000 | $ 2,440,000 |  |
Realized loss on RareStone equity |  |  |  | $ 1,040,000 |  |  |  |  |  |  |
Loss on RareStone equity investment |  |  |  |  | $ 300,000 |  |  |  |  |  |
Upfront consideration |  |  |  |  |  |  |  | 8,040,000 |  |  |
Number of performance obligations | item |  | 2 |  |  |  |  |  |  |  |  |
License agreement commercial manufacturing supply discount |  |  |  |  |  |  | 1,286,000 |  |  |  |
Contract with customer liability revenue recognized |  |  |  |  |  |  | 6,754,000 |  |  |  |
Ipsen | License agreement |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Amount of commercial milestone capitalized |  |  |  |  |  |  |  |  | $ 4,000,000 | $ 5,000,000 |
Milestone expenses |  |  |  |  |  | 0 | 0 | 0 |  |  |
Ipsen | License agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Aggregate payment upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  | $ 40,000,000
Ipsen | Sublicense agreement | Minimum |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Payment based on revenue received, as percentage |  |  |  |  |  |  |  |  |  |  | 10.00%
Ipsen | Sublicense agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Payment based on revenue received, as percentage |  |  |  |  |  |  |  |  |  |  | 20.00%
Camurus | License agreement |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Milestone expenses |  |  |  |  |  | 0 | 1,000,000 | 0 |  |  |
Non-refundable and non-creditable signing fee |  |  | $ 500,000 |  |  |  |  |  |  |  |
Royalty payment period |  |  | 10 years |  |  |  |  |  |  |  |
Camurus | License agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
One-time non-refundable development milestone payment |  |  | $ 7,750,000 |  |  |  |  |  |  |  |
One-time non-refundable non-creditable sales milestone payment |  |  | $ 57,000,000 |  |  |  |  |  |  |  |
Takeda |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Equity issued in conjunction with license agreement | 4,448,000 |  |  |  |  |  |  |  |  |  |
Milestone expenses |  |  |  |  |  | 0 | 0 | 0 |  |  |
One-time non-refundable development milestone payment | $ 70,000,000 |  |  |  |  |  |  |  |  |  |
Shares issued for license agreement (in shares) | shares | 223,544 |  |  |  |  |  |  |  |  |  |
Period after date of first commercial sale (in years) | 10 years |  |  |  |  |  |  |  |  |  |
License revenue |  |  |  |  |  |  |  |  |  |  |
Significant Agreements |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 0 | $ 6,754,000 | $ 0 |  |  |

X
- Definition Represent the amount of aggregate payment upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | rytm_AggregatePaymentUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of commercial milestone capitalized as a finite lived intangible asset from first commercial sale. + References No definition available. + Details
Name: | rytm_CommercialMilestoneAmountCapitalized
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of discount on commercial manufacturing supply in license agreement. + References No definition available. + Details
Name: | rytm_LicenseAgreementCommercialManufacturingSupplyDiscount
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of performance obligations in license agreement. + References No definition available. + Details
Name: | rytm_LicenseAgreementNumberOfPerformanceObligations
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront consideration received on license agreement. + References No definition available. + Details
Name: | rytm_LicenseAgreementUpfrontConsideration
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of milestone expenses. + References No definition available. + Details
Name: | rytm_MilestoneFee
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of non-refundable and non-creditable signing fee. + References No definition available. + Details
Name: | rytm_NonRefundableAndNonCreditableSigningFee
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of independent sub studies conducted in patients. + References No definition available. + Details
Name: | rytm_NumberOfIndependentSubStudiesInPatients
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of one-time non-refundable non-creditable sales milestone payment upon achievement of certain sales levels. + References No definition available. + Details
Name: | rytm_OnetimeNonRefundableNonCreditableSalesMilestonePaymentUponAchievementOfCertainSalesLevels
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of one-time non-refundable development milestone payment upon achievement of certain regulatory successes. + References No definition available. + Details
Name: | rytm_OnetimeNonrefundableDevelopmentMilestonePaymentUponAchievementOfCertainRegulatorySuccesses
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the percentage payment based on revenue received. + References No definition available. + Details
Name: | rytm_PaymentPercentageBasedOnRevenuesReceived
Namespace Prefix: | rytm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period after the date of the first commercial sale. + References No definition available. + Details
Name: | rytm_PeriodAfterDateOfFirstCommercialSale
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of realized gain (loss) on investment in Rarestone valuation. + References No definition available. + Details
Name: | rytm_RarestoneValuationRealizedGainLoss
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the period for royalty payment after first commercial sale. + References No definition available. + Details
Name: | rytm_RoyaltyPaymentPeriodAfterFirstCommercialSale
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period from license agreement. + References No definition available. + Details
Name: | rytm_StockIssuedDuringPeriodSharesNewIssuesLicenseAgreement
Namespace Prefix: | rytm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period from license agreement. + References No definition available. + Details
Name: | rytm_StockIssuedDuringPeriodValueNewIssuesLicenseAgreement
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of an upfront payment. + References No definition available. + Details
Name: | rytm_UpfrontPayment
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_GainLossOnContractTermination
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of other assets. + References No definition available. + Details
Name: | us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rytm_RareStoneGroupLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rytm_IpsenPharmaSasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rytm_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rytm_SublicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rytm_CamurusAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rytm_TakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |